FELIQS, an innovative Japanese startup at the forefront of biopharmaceutical research, is excited to announce that it has successfully raised $8,340,000 in its latest funding round. This significant influx of capital underscores the strong confidence that investors have in FELIQS鈥檚 vision and its groundbreaking approach to targeting multi-billion-dollar markets in ophthalmology and neonatology. With a total funding pool of $12 million already secured, the company is strategically positioned to advance its portfolio of two patent-protected drug product candidates designed to address critical unmet medical needs.
The funds will primarily support the development of FLQ-101 and FLQ-105, the company鈥檚 flagship candidates. FLQ-101, a repurposed lipid peroxidation inhibitor, is engineered to prevent retinopathy of prematurity (ROP), a severe eye disorder affecting newborns. The drug is slated to enter Phase I/II dosing trials in the United States in 2025, marking a significant step forward in neonatal care. Meanwhile, FLQ-105 is FELIQS鈥檚 proprietary solution for age-related macular degeneration (AMD), a leading cause of vision loss in older adults. As a dual-action inhibitor targeting both lipid peroxidation and ferroptosis, FLQ-105 is poised for a Phase I study in 2026 with the potential to offer earlier intervention strategies compared to current treatments.
This new investment will accelerate the clinical progression of these candidates, leveraging FELIQS鈥檚 proprietary screening platform that has already demonstrated promising efficacy in past clinical trials. With this latest funding milestone, FELIQS is not only reinforcing its commitment to pioneering novel therapies but also paving the way for significant advancements in the treatment of eye disorders, ultimately improving patient outcomes on a global scale.
